ApaTech expands into new facility:
This article was originally published in Clinica
ApaTech, an orthopaedic implants company spun out from Queen Mary, University of London, has gained £2m ($3.6) in funding from new investor Noble Venture Finance. The money will be used to fund the company's expansion, as it relocates from current university premises to a purpose-built facility in Elstree, Hertfordshire. The move will help ApaTech "to meet growing market demand and to introduce new products". The company, which has operations in the UK and US, produces synthetic bone graft materials for use in the orthopaedic and spinal fusion markets.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Commissioner Hahn’s tweet announcing a return to inspections, while not a new policy, may be signal that FDA understands sponsor concerns with the agency’s limited ability to conduct onsite inspections. Effort may be aimed at reassuring industry even as CRLs related to manufacturing increase.
Rushed final rule seeking to impose draconian cuts on drug reimbursement rates in the Medicare Part B program is certain to face legal and political obstacles. But the data included on international price benchmarks will still have an impact.